Literature DB >> 11049792

Empirical antimicrobial therapy for traveler's diarrhea.

J A Adachi1, L Ostrosky-Zeichner, H L DuPont, C D Ericsson.   

Abstract

Over 7 million cases of traveler's diarrhea, defined as the passage of > or = 3 unformed stools in a 24-h period, occur each year among visitors to developing countries. Bacterial enteric pathogens are the most common etiologic agents isolated. Preliminary clinical results for patients with diarrhea predominantly caused by Campylobacter species have shown that azithromycin may be an effective alternative to fluoroquinolones for the treatment of traveler's diarrhea.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11049792     DOI: 10.1086/318119

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

1.  Posttreatment changes in Escherichia coli antimicrobial susceptibility rates among diarrheic patients treated with ciprofloxacin.

Authors:  Shannon D Putnam; John W Sanders; David R Tribble; David R Rockabrand; Mark S Riddle; Patrick J Rozmajzl; Robert W Frenck
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

2.  Diarrhea in the returned traveler.

Authors:  J W Sanders; D R Tribble
Journal:  Curr Gastroenterol Rep       Date:  2001-08

3.  Update on Traveler's Diarrhea.

Authors:  Allen C. Cheng; Nathan M. Thielman
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

4.  Antimicrobial susceptibilities of Campylobacter strains isolated from Finnish subjects infected domestically or from those infected abroad.

Authors:  Hilpi Rautelin; Antti Vierikko; Marja-Liisa Hänninen; Martti Vaara
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

5.  Efficacy of pefloxacin in the treatment of patients with acute infectious diarrhoea.

Authors:  Biserka Troselj-Vukic; Ivica Poljak; Irena Milotic; Irena Slavic; Nebojsa Nikolic; Miro Morovic
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

Review 6.  Travelers with sickle cell disease.

Authors:  Shaina M Willen; Courtney D Thornburg; Paul M Lantos
Journal:  J Travel Med       Date:  2014-06-19       Impact factor: 8.490

7.  Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.

Authors:  Thomas R Fritsche; Douglas J Biedenbach; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

8.  Recent Advances and New Challenges in Travel Medicine.

Authors:  Lin H. Chen; Mary E. Wilson
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.663

9.  Increasing fluoroquinolone resistance in Campylobacter jejuni, Pennsylvania, USA,1982-2001.

Authors:  Irving Nachamkin; Huong Ung; Ming Li
Journal:  Emerg Infect Dis       Date:  2002-12       Impact factor: 6.883

10.  Trial Evaluating Ambulatory Therapy of Travelers' Diarrhea (TrEAT TD) Study: A Randomized Controlled Trial Comparing 3 Single-Dose Antibiotic Regimens With Loperamide.

Authors:  Mark S Riddle; Patrick Connor; Jamie Fraser; Chad K Porter; Brett Swierczewski; Emma J Hutley; Brook Danboise; Mark P Simons; Christine Hulseberg; Tahaniyat Lalani; Ramiro L Gutierrez; David R Tribble
Journal:  Clin Infect Dis       Date:  2017-11-29       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.